Need for multicriteria evaluation of generic drug policies

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Zoltán KalóDiana Brixner

Abstract

Policymakers tend to focus on improving patented drug policies because they are under pressure from patients, physicians, and manufacturers to increase access to novel therapies. The success of pharmaceutical innovation over the last few decades has led to the availability of many off-patent drugs to treat disease areas with the greatest public health need. Therefore, the success of public health programs in improving the health status of the total population is highly dependent on the efficiency of generic drug policies. The objective of this article was to explore factors influencing the true efficiency of generic prescription drug policies in supporting public health initiatives in the developed world. Health care decision makers often assess the efficiency of generic drug policies by the level of price erosion and market share of generics. Drug quality, bioequivalence, in some cases drug formulations, supply reliability, medical adherence and persistence, health outcomes, and nondrug costs, however, are also attributes of success for generic drug policies. Further methodological research is needed to measure and improve the efficiency of generic drug policies. This also requires extension of the evidence base of the impact ...Continue Reading

References

Sep 27, 2003·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Rita R AllowaySteven K Takemoto
Sep 21, 2004·CNS Drugs·Philippe NussMartina Hummer
Sep 7, 2006·International Journal of Geriatric Psychiatry·Anna R HuizingFrans R J Verhey
Jun 23, 2007·Health Economics·Patrick ThiebaudMichael B Nichol
Jul 5, 2007·JAMA : the Journal of the American Medical Association·Dana P GoldmanYuhui Zheng
Jul 30, 2009·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Tom Stargardt
Aug 28, 2009·Current Medical Research and Opinion·Helle HåkonsenElse-Lydia Toverud
Mar 20, 2010·Advances in Therapy·Helle HåkonsenElse-Lydia Toverud
Apr 14, 2010·The Journal of Clinical Psychiatry·Jonathan R T Davidson
Aug 19, 2010·British Journal of Clinical Pharmacology·Atholl JohnstonGeorge S Stergiou
Aug 19, 2010·British Journal of Clinical Pharmacology·Martin G Duerden, Dyfrig A Hughes
Nov 26, 2010·Expert Review of Neurotherapeutics·Josemir W SanderJürgen Bauer
Nov 26, 2010·European Journal of Clinical Pharmacology·Else-Lydia ToverudInger Wabø
Dec 1, 2010·CNS Neuroscience & Therapeutics·Julie Eve DesmaraisHoward C Margolese
Dec 16, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Brian GodmanLars L Gustafsson
Dec 17, 2010·European Journal of Clinical Pharmacology·Helle Håkonsen, Else-Lydia Toverud
May 27, 2011·International Journal of Clinical Pharmacology and Therapeutics·K KostevU May
Jul 30, 2011·PharmacoEconomics·Pieter Dylst, Steven Simoens
Nov 29, 2011·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·O Ström, E Landfeldt
Jul 24, 2012·BMC Pulmonary Medicine·Zoltan KaloZoltan Voko
Oct 9, 2012·Pharmacoepidemiology and Drug Safety·Jon DukeXiaochun Li
Jan 2, 2013·JAMA Internal Medicine·Aaron S KesselheimNiteesh K Choudhry
Apr 4, 2013·International Journal of Clinical Pharmacology and Therapeutics·Karel KostevLilia Waehlert
Aug 13, 2014·Journal of the American Society of Nephrology : JASN·Efrain ReisinMahboob Rahman

❮ Previous
Next ❯

Citations

Aug 10, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·András InotaiZoltán Kaló
Dec 8, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·András Inotai, Zoltán Kaló
Apr 24, 2020·Expert Review of Pharmacoeconomics & Outcomes Research·Zsuzsanna Ida PetykóZoltán Kaló
Sep 13, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·András HarsányiAndrás Inotai
Oct 1, 2016·Journal of Pharmaceutical Policy and Practice·Chia-Ying LeeJodi B Segal
Jul 11, 2018·Applied Health Economics and Health Policy·Nikolaos ManiadakisKalman Wijaya
Apr 24, 2019·Journal of Pharmaceutical Policy and Practice·Ali Hadi AbdullahZoltán Kaló
Sep 26, 2020·Frontiers in Public Health·Tomas TesarAndrás Inotai
Jun 16, 2021·Journal of Pharmaceutical Policy and Practice·Anke-Peggy HoltorfNapassorn Apinchonbancha
Jun 26, 2021·Frontiers in Pharmacology·Mohamed Naser FarghalyZoltán Kaló
Jul 10, 2021·Journal of Comparative Effectiveness Research·Brian GodmanJohanna C Meyer
Sep 2, 2021·Cost Effectiveness and Resource Allocation : C/E·Zsuzsanna Ida PetykóAndrás Inotai

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved